All In Biotech

Drug Trial Radar · NCT07426484

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster)

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Dec 15, 2030

Study completion Dec 15, 2032

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Checkpoint Therapeutics, Inc.
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)

Conditions

  • Cutaneous Squamous Cell Carcinoma
  • Skin Cancer

Interventions

  • CosibelimabDrug

    Anti-PD-L1 antibody, single dose vials, via intravenous (into the vein) infusion per protocol

  • PrednisoneDrug

    Corticosteroid, per standard of care

  • SirolimusDrug

    mTOR Inhibitor, per standard of care

  • EverolimusDrug

    mTOR Inhibitor, per standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate (BORR)Time frame: Up to 102 weeks.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.